Using the New Therapeutic Options in Multiple Myeloma
Published Online: Friday, April 5, 2013
Sundar Jagannath, MD
With the approval of carfilzomib in July 2012 and pomalidomide in February 2013, new therapeutic options are available for the treatment of multiple myeloma (MM). At the 17th Annual International Congress on Hematologic Malignancies, Sundar Jagannath, MD, professor of Medicine and Director, Multiple Myeloma Program, The Tisch Cancer Institute at Mount Sinai Medical Center, New York City, spoke about evidence for use of these treatment options in clinical practice.
Thalidomide, lenalidomide, and pomalidomide are structurally similar, but functionally they are different, both qualitatively and quantitatively, said Jagannath. “That’s very important when we talk about having a new drug for the treatment of relapsed and refractory multiple myeloma.” Mechanisms that lead to resistance with lenalidomide and thalidomide do not necessarily impact the use of pomalidomide, he said.
MM-002 was the pivotal trial that led to the approval of pomalidomide.1 The study examined the use of pomalidomide in combination with low-dose dexamethasone in patients with relapsed and refractory MM who had received two or more prior therapies, including lenalidomide and bortezomib. At the 2012 American Society of Hematology (ASH) meeting in December, Jagannath presented updated results of the phase II study, including an age subgroup analysis.
Figure. Developments in Multiple Myeloma Research
Adapted from Anderson KC. Bench to bedside translation of targeted therapies in multiple myeloma.
Presented at 2011 American Society of Clinical Oncology Annual Meeting; June 4, 2011; Chicago, Il.
The overall response rate (ORR) was 34% in the combination therapy group versus 15% in the pomalidomide- alone group. The median progression-free survival (PFS) in the pomalidomide/dexamethasone group was 4.6 months versus 2.6 months for the pomalidomide- alone group (hazard ratio [HR] = 0.67; P = .002).
However, the median duration of response was the same in both groups: 8.3 months for pomalidomide plus dexamethasone versus 8.8 months for pomalidomide alone (HR = 0.89; P = .734). “At this stage [of the disease], it’s not that dexamethasone is the key. It does synergize, but pomalidomide is the key, and there is a durability of the response if [patients] do respond,” Jagannath said.
Overall survival (OS) was the same in the two treatment arms (16.5 months for pomalidomide/dexamethasone vs 13.6 months for pomalidomide alone; HR = 0.92; P = .609).
Pomalidomide was generally well tolerated and did not cause as significant neutropenia as generally occurs with lenalidomide, or as significant neuropathy as occurs with thalidomide, Jagannath said. The most common grade 3 or 4 adverse events (AEs) occurring in more than 5% of study participants were neutropenia (41%), anemia (22%), pneumonia (22%), thrombocytopenia (19%), fatigue (14%), dyspnea (13%), leukopenia (10%), back pain (10%), and urinary tract infection (9%).1
Neutropenia occurred in nearly 60% of patients older than 65 years in the pomalidomide-only group, Jagannath said, “so there are significant adverse events in these patients.” Furthermore, he said, “when you combine [pomalidomide] with dexamethasone, especially in the elderly patient, you have to be careful…because the incidence of pneumonia is a little higher.” Jagannath also noted that rates of deep vein thrombosis were very low (2%, all grades) because patients received anticoagulation.
Most Popular Right Now
Online CME Activities